#Canada #Duchesnay #ADRIQ #Éric Gervais #Blainville

Duchesnay Pharmaceutical Group: Celebrating the 2024 Life Sciences Innovation Award

In a prominent celebration of innovation, the Duchesnay Pharmaceutical Group (DPG) has been honored with the 2024 Life Sciences Innovation Award by the ADRIQ (Association for the Development of Research and Innovation of Quebec). This prestigious recognition was presented at a gala event in Montreal, held on November 21, highlighted by the presence of industry leaders and innovators. The award celebrated DPG's commitment to innovation, its strong workplace culture, and its impactful contributions to the pharmaceutical landscape in Quebec and beyond.

Éric Gervais, the President of DPG, expressed immense pride in receiving this award, stating, “This accolade acknowledges the culture of innovation we nurture at DPG and our successful efforts in not only advancing our business but also aiding patients in Quebec, Canada, the U.S., and globally.” His sentiments reflect a deep commitment to enhancing healthcare and responding to patient needs through pharmaceutical advancements.

In addition to the company award, Gervais was individually honored with the Prix Bernard-Landry, recognizing his exceptional influence on pharmaceutical innovation within Quebec over the past three decades. He remarked on the gratifying nature of the acknowledgment, attributing it to the relentless efforts of his talented team dedicated to research and new product development. Michael Gallo, Vice President of Regulatory and Medical Affairs, echoed these sentiments, highlighting how the award reinforces DPG's role in providing innovative treatments for women and patients with rare diseases.

Duchesnay has long been a leader in developing treatments aimed at managing nausea and vomiting of pregnancy (NVP), carving out a niche as a Canadian innovator in this critical area. The company's products are not only approved for use in Canada and the U.S. but are also accessible in over 40 countries within the past two years alone, with plans to expand to more than 60 international markets in the near future.

This achievement reflects DPG's longstanding commitment to women’s health, with a dedicated division focused on developing and marketing essential pharmaceutical treatments. Manon Vranderick, Vice President of Product Development and Manufacturing Strategy, expressed her pride in the team’s collective accomplishments, emphasizing DPG’s continuous evolution and capacity to innovate to benefit patients worldwide.

Currently, DPG is actively progressing with research and development projects, including the exploration of new contraceptive options and treatments for multiple sclerosis in collaboration with a leading international research organization. This strategic direction underscores DPG’s commitment to enhancing its operational structure and expanding its production capabilities to satisfy the rising demand for its unique treatment offerings.

The company’s vision revolves around creating a better world through excellence and innovation, a philosophy embodied in its recent expansion efforts and the establishment of various subsidiaries, the latest being Analog Pharma Canada. Such diversification allows DPG to sustain its robust research and development initiatives, further promoting advancements within the healthcare sector.

Recent years have witnessed substantial growth for DPG, characterized by rising revenues, substantial investments in research and development, and an expanding workforce. Since Gervais joined the company, he has been pivotal in driving growth, including the formation of new companies across Canada and the U.S. as well as securing international partnerships via strategic licensing agreements.

About ADRIQ

Founded in 1978, ADRIQ fosters a collaborative ecosystem focused on research and innovation within Quebec. It serves as a crucial platform for partnerships that enhance commercialization processes and drive the success of its members.

About Duchesnay Pharmaceutical Group

Headquartered in Blainville, Quebec, Duchesnay Pharmaceutical Group comprises six companies specializing in women's health and treatment for rare diseases. DPG emphasizes environmental responsibility and is committed to community engagement, exemplified by its support of various charitable organizations. For more information on DPG’s initiatives and products, visit their official site.